PUVA therapy | |
---|---|
MeSH | D011701 |
PUVA (psoralen and ultraviolet A) is an ultraviolet light therapy treatment for eczema, psoriasis, graft-versus-host disease, vitiligo, mycosis fungoides, large-plaque parapsoriasis and cutaneous T-cell lymphoma using the sensitizing effects of the drug psoralen. The psoralen is applied or taken orally to sensitize the skin, then the skin is exposed to UVA.
Photodynamic therapy is the general use of nontoxic light-sensitive compounds that are exposed selectively to light, whereupon they become toxic to targeted malignant and other diseased cells. Still, PUVA therapy is often classified as a separate technique from photodynamic therapy.
Psoralens are materials that make the skin more sensitive to UV light. They are photosensitizing agents and are found in plants naturally and also manufactured synthetically. Psoralens are taken as pills (systemically) or can be applied directly to the skin, by soaking the skin in a solution that contains the psoralens. They allow UVA energy to be effective at lower doses. When combined with exposure to the UVA in PUVA, psoralens are highly effective at clearing psoriasis and vitiligo. In the case of vitiligo, they work by increasing the sensitivity of melanocytes, the cells that manufacture skin color, to UV light. Melanocytes have sensors that detect UV light and trigger the manufacture of brown skin color. This color protects the body from the harmful effects of UV light. It can also be connected to the skin's immune response.
The physician can choose a starting dose based on the patient's skin type. The dose will increase in every treatment until the skin starts to respond, normally when it becomes a little bit pink.
Some clinics test the skin before the treatments, by exposing a small area of the patient's skin to UVA, after ingestion of psoralen. The dose of UVA that produces uniform redness 12 hours later, called the minimum phototoxic dose (MPD), or minimal erythema dose (MED) becomes the starting dose for treatment.